Highlighted in Figure are potential gene targets with the highest publication frequency in the CRISPR dataset (journals and patents from 1995 to 2024). TP53, c-myc and hemoglobin beta subunit (HBB) genes were the top 3 occurring genes identified. As per Figure , the publication trend for TP53 has particularly shown rapid increase over the past few years. As shown in Figure , a majority of publications appear to be focused on cancer (35% of all journal articles and 24% of all patents), followed by infectious diseases (25% and 22% of journal articles and patents, respectively). Year-wise publication trends also shows remarkable and consistent increase in number of CRISPR articles focused on these two diseases after 2016. Other broader categories of disease conditions observed in the dataset were blood disorders, genetic disorders, nervous system disorders, cardiovascular diseases, respiratory diseases, immune diseases and metabolic disorders. In the following section we have discussed briefly how CRISPR/Cas technology is being utilized in the therapy targeted for these diseases with an emphasis on cancer, infectious diseases, blood disorders, genetic disorders (common as well as rare) and nervous system disorders.